REIMAR C. BRUENING Fremont, CA 94536 Ph/Fax: 510-894-3611/-4302 rb12ec544@westpost.

net

647 Pickering Avenue.

PROFILE Entrepreneur and self-starter with successful executive career as CEO, Senior VP , VP, Chief Scientist, and strategic/scientific advisor in the Life Sciences, Nu traceuticals and Renewable Energy Industries. Positive track record in setting and implementing corporate strategy, branding, team building and fund raising. Orthogonal thinker, inter-disciplinarian, inter-cultural communicator, leader, c onsensus builder and mentor: If you got a map, you can always find a way around the road-block in front of you! Visionary, sets high-but-realistic goals and works with team to achieve them in time. Agent of change, who applies principles of evolution to further corporate compet itiveness and adaptation. Expert witness in pharma-related litigation cases. SKILLS Thorough understanding of the drug discovery & development process. Expert in se paration and analytical instrumentation. Strategic planning and execution. Creat ive problem solving. Strong sense for quality in design and execution. Quick ada ptation to change. Good listener. Leading by example and with fairness, honesty and loyalty. Mentoring and motivating of associates and peers. Languages: English (fluent), German (fluent); Japanese, Italian, French (basic), Spanish (basic). EXPERIENCE and ACCOMPLISHMENTS (Position, >Results and Deliverables) FOUNDER AND PRESIDENT ADELPHI ALLIANCES LLC, FREMONT, CA (International business development and consultancy firm for life sciences-based companies) 2000 - present Client 1 (US-China pharmaceutical CRO) > Securing new clients among West Coast pharmaceutical- and biotech companies. Client 2 (Bio-fuel from micro-algae start-up): > Delivered: A focused corporate identity and strategy (sustainable production o f bio-fuels w/o negative impact on agricultural resources, and zero-carbon balan ce). A first-class international specialist team. A uniquely suitable location f or operations. Detailed financial forecast and emphasis on unique selling point( R) and competitive advantage. Secure process IP. Client 3 (instrumentation for supercritical fluid chromatography) > Delivered: A focused corporate identity and strategy (correct positioning of u nique IP portfolio based on in-depth analysis of market needs; branding). Produc t specs and pipeline. Key personnel under contract. Representative investor pack age. Client 4 (drug discovery from natural products): > Delivered: Innovative and competitive product concept (drug discovery library based on combinatorial modification of bio-active natural products). Product dev elopment plan, new key personnel and optimal CRO contracts. Client 5 (chemistry CRO): > Delivered: Invitations to present at major European pharmaceutical companies. Multi-million dollar contract manufacturing deal with BASF (Germany). Clients 6&7 (drug discovery): > Delivered: In-depth analysis of proprietary processes and ongoing operations. Road-map to overcome fundamental flaws through cutting-edge data handling, re-or

ganization, budget re-allocation and staff changes. SENIOR VICE PRESIDENT, PRODUCT DEVELOPMENT BIONAUT PHARMACEUTICALS (systems biology-based drug discovery) CAMBRIDGE, MA 2004-2005 (75% retainer-based) > Delivered a most promising drug candidate molecule culled from internal platfo rm hits. Implemented two-track strategy to secure IP estate (3 applications filed interna tionally) and to position original compound (a known cardiovascular drug) for I ND filing and exploratory Phase IIa clinical study for new anti-cancer indicatio n. Provided pre-clinical development plan for lead compound, incl. budget and timelines. Implemented and supervised cost-effective collaborations with the most suitable chemistry, manufacturing and clinical CROs in the US and Europe for pre-clinical development, GMP-manufacturing of drug substance, and Phase IIa clinical testin g and monitoring in breast cancer patients. PRESIDENT and CEO INGENIUM PHARMACEUTICALS (start-up; target discovery by mouse genomics) MARTINSRIED, GERMANY 1998-2000 > Secured platform IP (transfer from founding government research organization). Developed focused corporate strategy and 5-year business plan. Hired key personnel and put matrix-management structure in place. Conducted identification of and Due-Diligence on suitable M&A candidate companie s in Scotland and Hungary to widen and hedge IP portfolio. Secured additional funding from government and private investment banks. Deliver ed increase of post-money valuation from 10 to 45 million DM Initiated second investment round (closed at 80 million DM). Acting CSO NEXT PHARMACEUTICALS (Neutraceuticals) IRVINE, CA 1998 (sanctioned by Millennium) > Delivered innovative product platform (NEXTRACT(R)) providing the company with Unique Selling Point(R) in highly competitive market. Secured exclusive license for unique supercritical fluid-based technology for pr oduction of high-value chemicals from process stream. Provided design of work flow-based GMP facility. DIRECTOR, Natural Products Research MILLENNIUM PHARMACEUTICALS (MPI) (Functional genomics-based target- and drug discovery) CAMBRIDGE, MA 1997-1998 > Organized unique program for discovery of innovative anti-infective drug candi dates from trans-genic micro-organisms. Implemented novel one-process methodology for high-throughput production, fermen tation, extraction, bio-activity assessment, and compound identification. Delivered 4-fold increased discovery output compared to then-current industry st andard. Implemented comprehensive bug-to-hit tracking database. Developed entirely new FTIR-based assay technology (patented). Designed plan and infrastructure for in-house pre-clinical development (DMPK and

ADME-Tox). Conducted in-depth program presentation as part of the successful negotiations w ith Bayer Healthcare, resulting in the by-then largest Pharma-Biotech deal. VICE PRESIDENT, Chemistry CHEMGENICS PHARMACEUTICALS (natural products drug discovery) CAMBRIDGE, MA 1995-1997 > Re-organized, focused and streamlined drug discovery program. Developed 5-year strategic plan. Implemented matrix management structure using on-line Gannt-charts as discovery success metrics. Supervised Integration of new technologies and staff after partial merger with P erseptive Biosystems. Presented a credible discovery program fostering collaborations with Pfizer and Wyeth. Provided Net-Present-Value analysis of drug discovery program as part of success ful M&A negotiations with Millennium. CHIEF SCIENTIST SHAMAN PHARMACEUTICALS (Traditional medicine-based drug discovery) SOUTH SAN FRANCISCO, CA 1990-1995 > Provided blueprints for laboratories, project work-flow and success metrics. Developed and implemented novel bio-assay-guided extraction and isolation proces s platform involving first-time use of supercritical fluid technology. Provided drug candidate molecules (anti-diabetics and anti-fungals) for pre-clin ical development. Conducted value-descriptive presentations of R&D programs to investors and inves tment banks for successful IPO, and to potential partners in Japan, resulting in R&D deal with Ono Pharmaceuticals. Implemented company-wide research database. 4 patents filed and granted. ASSISTANT PROFESSOR UNIVERSITY OF HAWAII 1985-1990 > Conducted organic chemistry classes and lab courses on all levels. Developed first-in-US graduate course on Perfume Chemistry. Conducted two independent research programs: anti-cancer compounds from marine o rganisms, and signal chemistry in pelagic tuna. Secured 45,000 dollar in external funding. Received Presidential Citation for Excellence in Teaching. SR. RESEARCH ASSOCIATE COLUMBIA UNIVERSITY 1981-1985 > Solved 75-year old biochemical puzzle: the blood chemistry of vanadium-collect ing tunicates. Conducted introduction and transfer of pioneering new technology (centrifugal pa rtition chromatography) to the US from Japan. Researched and identified unusual blood ligands in patients with multiple myelom a. EDUCATION Columbia University Business School (1993): "Executive Management for the Pharmaceutical Industry" program, Trainee

Nagoya University, Japan (1979-1981): Postdoctoral research fellow (Synthetic Organic Chemistry) Stanford University (1978): Invited research under-graduate student (Computerized Mass Spectroscopy) University of Munich, Germany: Ph.D. (natl. prod. chemistry) summa cum laude.(1979) B.S in pharmacy (1974). Government of the State of Bavaria, Germany (1975): Registered Pharmacist in the European Union